Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread

The presence of intraductal carcinoma of the prostate (IDCP) correlates with late-stage disease and poor outcomes for patients with prostatic adenocarcinoma, but the accurate and reliable staging of disease severity remains ed to overcome problems in assessing IDCP morphology, but the current markers have only demonstrated limited utility in characterising the complex biology of this lesion. carcinoma. Cribriform IDCP displayed strong Appl1, Sortilin and Syndecan-1 labelling patterns, while solid adenocarcinoma, and also comparable to prostate cancer Sortilin, and Syndecan-1 biomarker panel in IDCP prosystem.

Automated summary

The presence of intraductal carcinoma of the prostate (IDCP) is associated with late-stage disease and poor outcomes. However, accurately assessing disease severity remains a challenge. Current markers have limited utility in characterizing the complex biology of IDCP.